Christopher (Chris) Stevenson joined Engitix in September 2023 as Chief Scientific Officer.

He has a strong track record of driving innovation and developing talented teams to propel science into novel therapeutic and diagnostic solutions for patients. Chris is responsible for leading Engitix’ scientific and translational strategy, which is focused on advancing a portfolio of novel therapies towards IND-enabling studies and eventually trials in patients with fibrotic diseases and solid tumours. He is also leading the company’s R&D Pharma partnerships centred on its novel platform technologies.

He joined Engitix from Johnson & Johnson, where he most recently served as Vice President, Global Head of Pharmaceutical Sciences for Interventional Oncology. In this role he was responsible for building a team to support discovery through early development programmes and delivering a portfolio of clinical-stage assets, which included multiple cancer immunotherapies and the licensing of NBTXR3 from Nanobiotix.

Prior to this role, Chris headed discovery and translational biology units at Respivert, Novartis and Roche. Over his career, Chris has led the discovery or contributed to the development of over 10 drug candidates aiming to treat fibrosis, inflammation or cancers, as well as authoring over 60 peer reviewed papers and patents.

He received his Doctorate and Bachelor of Science degrees from the University of California, Santa Barbara, USA.